Drug development for chronic hepatitis B functional cure:Recent progress  

作　　者：Ting Liu He Wang Yue Zhao Ying-Xin Wang Xue Xing Peng Gao 

机构地区：[1]Department of Clinical Laboratory,The Second Affiliated Hospital of Dalian Medical University,Dalian 116021,Liaoning Province,China [2]Graduate School Base Office,Dalian Medical University,Dalian 116000,Liaoning Province,China

出　　处：《World Journal of Hepatology》2025年第4期31-42,共12页世界肝病学杂志(英文)

摘　　要：Chronic hepatitis B virus(HBV)infection affects approximately 254 million individuals globally,contributing to significant morbidity and mortality due to HBV-related liver failure and cirrhosis,which result in millions of fatalities each year.Although approved antiviral nucleos(t)ide analogues can effectively suppress HBV replication,their ability to reduce hepatitis B surface antigen(HBsAg)levels in plasma remains limited.The clinical application of the immunomodulator interferon-alpha is restricted by concerns regarding its safety and the severity of associated adverse reactions,rendering long-term administration challenging.Therefore,current drug development efforts for chronic hepatitis B aim to achieve a functional cure,which is defined as HBsAg serological clearance and sustained suppression of HBV DNA.This review discusses recent advancements in novel direct-acting therapeutic strategies for the treatment of chronic hepatitis B by focusing on the progresses in HBV entry inhibitors,monoclonal antibodies,RNA interferences,and other agents that directly target the virus.Furthermore,we discuss the development of immunomodulatory therapies,including TLR-7/8 agonists,immune checkpoint inhibitors,and therapeutic vaccines.In the end,we conclude by highlighting the importance of the rational combination-strategy design to improve the functional cure rate of HBV.

关 键 词：Chronic hepatitis B infection Therapeutic targets Monoclonal antibody RNA interference IMMUNOMODULATORS 

分 类 号：R51[医药卫生—内科学]